Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest of Verve Therapeutics, Inc. from 31 Dec 2020 to 31 Mar 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.
Summary
Verve Therapeutics, Inc. quarterly and annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest in USD history and change rate from 31 Dec 2020 to 31 Mar 2025.
  • Verve Therapeutics, Inc. Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for the quarter ending 31 Mar 2025 was $30,954,000, a 36% increase year-over-year.
  • Verve Therapeutics, Inc. Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for the twelve months ending 31 Mar 2025 was $180,684,000, a 8% increase year-over-year.
  • Verve Therapeutics, Inc. annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for 2024 was $198,360,000, a 0.72% increase from 2023.
  • Verve Therapeutics, Inc. annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for 2023 was $199,793,000, a 27% decline from 2022.
  • Verve Therapeutics, Inc. annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for 2022 was $157,334,000, a 31% decline from 2021.
Source SEC data
View on sec.gov
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, Trailing 12 Months (USD)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, Quarterly (USD)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, YoY Quarterly Change (%)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, Annual (USD)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, YoY Annual Change (%)

Verve Therapeutics, Inc. Quarterly Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q1 2025 $180,684,000 $30,954,000 +$17,676,000 +36% 01 Jan 2025 31 Mar 2025 10-Q 14 May 2025 2025 Q1
Q4 2024 $198,360,000 $49,962,000 -$1,642,000 -3.4% 01 Oct 2024 31 Dec 2024 10-K 27 Feb 2025 2024 FY
Q3 2024 $196,718,000 $50,029,000 -$4,338,000 -9.5% 01 Jul 2024 30 Sep 2024 10-Q 05 Nov 2024 2024 Q3
Q2 2024 $192,380,000 $49,739,000 +$4,068,000 +7.6% 01 Apr 2024 30 Jun 2024 10-Q 08 Aug 2024 2024 Q2
Q1 2024 $196,448,000 $48,630,000 +$3,345,000 +6.4% 01 Jan 2024 31 Mar 2024 10-Q 14 May 2025 2025 Q1
Q4 2023 $199,793,000 $48,320,000 01 Oct 2023 31 Dec 2023 10-K 27 Feb 2025 2024 FY
Q3 2023 $45,691,000 -$501,000 -1.1% 01 Jul 2023 30 Sep 2023 10-Q 05 Nov 2024 2024 Q3
Q2 2023 $53,807,000 -$12,861,000 -31% 01 Apr 2023 30 Jun 2023 10-Q 08 Aug 2024 2024 Q2
Q1 2023 $51,975,000 01 Jan 2023 31 Mar 2023 10-Q 08 May 2024 2024 Q1
Q3 2022 $45,190,000 01 Jul 2022 30 Sep 2022 10-Q 07 Nov 2023 2023 Q3
Q2 2022 $40,946,000 01 Apr 2022 30 Jun 2022 10-Q 10 Aug 2023 2023 Q2

Verve Therapeutics, Inc. Annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $198,360,000 +$1,433,000 +0.72% 01 Jan 2024 31 Dec 2024 10-K 27 Feb 2025 2024 FY
2023 $199,793,000 -$42,459,000 -27% 01 Jan 2023 31 Dec 2023 10-K 27 Feb 2025 2024 FY
2022 $157,334,000 -$37,020,000 -31% 01 Jan 2022 31 Dec 2022 10-K 27 Feb 2025 2024 FY
2021 $120,314,000 -$74,610,000 -163% 01 Jan 2021 31 Dec 2021 10-K 27 Feb 2024 2023 FY
2020 $45,704,000 01 Jan 2020 31 Dec 2020 10-K 02 Mar 2023 2022 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.